You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2025

CLINICAL TRIALS PROFILE FOR CLOBETASOL PROPIONATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Clobetasol Propionate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00189397 ↗ Azathioprine Versus Corticosteroids in Parthenium Dermatitis Completed All India Institute of Medical Sciences, New Delhi N/A 2003-02-01 The dermatitis caused by the substances which come in contact with the skin is known as contact dermatitis. When such a reaction is caused by the agents suspended in the air, it is called air-borne contact dermatitis (ABCD). Parthenium hysterophorus at present is the commonest cause of ABCD in India though in some cases other plants have also been found to cause ABCD. Parthenium dermatitis is one of the major health problems in dermatology in our country. Though it has very little mortality, the disease normally continues to persist with variable remissions and relapses causing great distress and morbidity. Corticosteroids, topical and systemic have been the mainstay of the treatment so far. Therefore, the patients with ABCD who have to take corticosteroids for long periods of time tend to develop severe and sometimes irreversible side effects of the therapy. Azathioprine is an immunosuppressive drug which acts by inhibiting the T lymphocytes. In our previous studies we have been able to induce remissions in these patients with azathioprine used as daily as well as monthly bolus dose, without having to use systemic corticosteroids. The side effect with azathioprine in these studies were almost absent. We have therefore planned to study the therapeutic efficacy of azathioprine weekly pulse doses versus daily azathioprine in achieving remissions in patients having Parthenium dermatitis and to monitor the side effects of both the regimens.
NCT00288769 ↗ Oral Vitamin B12 as Potential Treatment of Recurrent Aphthous Stomatitis Completed Soroka University Medical Center N/A 2006-03-01 Background: Recurrent aphthous stomatitis is a common phenomenon in Primary Medicine.Frequency of the phenomenon can be as high as 25% of the general population and the recurrence of the problem can be up to 50%.Different approaches for treatment are described: treatment with various natural vitamins , local ointments , disinfectant agents for local treatment , local antibiotic ointments , NSAID, local cortisone-steroids , and even medication on the basis of immune-depressants of the immune system and systematic steroids . Methods: A double-blind study of daily administration of sublingual Vitamin B12 tablets manufactured by Solgar (each tablet containing 1000 mcg. of Vitamin B12) opposed to placebo tablets. Purpose of the research: To investigate the effect of Vitamin B12 on the frequency of recurrent canker sores of the mouth (RAS). Study hypothesis: Treatment with vitamin B12 will reduce the recurrence rate and will diminish the symptomatology of RAS episodes.
NCT00436540 ↗ A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam Completed Galderma Laboratories, L.P. Phase 4 2006-03-01 The primary objective of this study is to evaluate the efficacy and safety of clobetasol propionate 0.05% (Clobex®) spray compared to clobetasol propionate 0.05% (Olux®) foam.
NCT00437255 ↗ Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis Completed Galderma Laboratories, L.P. Phase 4 2006-08-01 Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.
NCT00438399 ↗ Subject Preference for Scalp Psoriasis Treatment Completed Galderma Phase 3 2007-02-01 The scalp is one of the most common affected sites in psoriatic patients as 79% of them have scalp involvement.It has also a psychological aspect with 31% of patients with scalp psoriasis indicating distress. Topical agents remain the mainstay of treatment for scalp psoriasis. However, they are not always ideal because they might be inconvenient and messy to use, stain or damage hair. The test shampoo, Clobetasol propionate Shampoo 0.05% (marketed in the USA under the tradename of Clobex®) was developed to provide the strongest available corticosteroid as a short-contact therapy in order to improve the chances of it being effective and reduce the potential for traditional side-effects. The objective of this study is to compare subject's overall preference between Clobetasol propionate shampoo 0.05% and three other topical corticosteroids in the treatment of moderate to severe scalp psoriasis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Clobetasol Propionate

Condition Name

Condition Name for Clobetasol Propionate
Intervention Trials
Psoriasis 13
Vulvar Lichen Sclerosus 6
Oral Lichen Planus 6
Plaque Psoriasis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Clobetasol Propionate
Intervention Trials
Psoriasis 23
Lichen Sclerosus et Atrophicus 8
Lichen Planus, Oral 8
Lichen Planus 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Clobetasol Propionate

Trials by Country

Trials by Country for Clobetasol Propionate
Location Trials
United States 114
France 9
Germany 8
Canada 6
Brazil 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Clobetasol Propionate
Location Trials
California 13
Texas 11
New York 9
Florida 5
North Carolina 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Clobetasol Propionate

Clinical Trial Phase

Clinical Trial Phase for Clobetasol Propionate
Clinical Trial Phase Trials
Phase 4 19
Phase 3 15
Phase 2/Phase 3 3
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Clobetasol Propionate
Clinical Trial Phase Trials
Completed 47
Recruiting 7
Unknown status 7
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Clobetasol Propionate

Sponsor Name

Sponsor Name for Clobetasol Propionate
Sponsor Trials
Galderma Laboratories, L.P. 7
GlaxoSmithKline 5
Stiefel, a GSK Company 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Clobetasol Propionate
Sponsor Trials
Other 47
Industry 44
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projections for Clobetasol Propionate

Last updated: July 16, 2025

Introduction

Clobetasol Propionate, a potent topical corticosteroid, remains a cornerstone treatment for inflammatory skin conditions such as psoriasis, eczema, and dermatitis. First approved by the U.S. Food and Drug Administration (FDA) in 1985, this drug generates significant revenue through generic formulations, with global sales exceeding $500 million annually [1]. As dermatological disorders affect over 230 million people worldwide, demand for effective therapies like Clobetasol Propionate continues to grow [2]. This article examines recent clinical trial developments, current market dynamics, and future projections, providing actionable insights for pharmaceutical stakeholders, investors, and healthcare professionals.

Clinical Trials Update

Recent clinical trials for Clobetasol Propionate have focused on enhancing efficacy, reducing side effects, and exploring new delivery methods, driven by the need to address limitations such as skin atrophy and systemic absorption. A Phase III trial completed in 2023 by Glenmark Pharmaceuticals investigated a novel foam formulation for plaque psoriasis, demonstrating superior lesion clearance rates compared to traditional creams, with 72% of patients achieving a 75% improvement in the Psoriasis Area and Severity Index (PASI) by week 4 [3]. This trial, registered on ClinicalTrials.gov (NCT04789186), underscores the drug's potential in more patient-friendly formats, potentially improving adherence.

Another key development involves combination therapies. A 2022 study published in the Journal of the American Academy of Dermatology evaluated Clobetasol Propionate alongside calcipotriene for moderate-to-severe psoriasis, reporting enhanced efficacy with a 15% greater reduction in erythema and scaling versus monotherapy [4]. This trial highlighted reduced relapse rates over six months, positioning the drug as a viable option in long-term management protocols.

Ongoing trials are also addressing pediatric applications, where safety concerns have historically limited use. For instance, a Phase II trial by Bausch Health, initiated in 2024, assesses low-dose Clobetasol Propionate for atopic dermatitis in children aged 2-12 (NCT05930550). Preliminary data suggest comparable efficacy to adults with a lower incidence of adverse events, such as hypothalamic-pituitary-adrenal axis suppression, occurring in less than 5% of participants [5]. These advancements could expand market access, particularly in regions with high pediatric dermatological burdens.

Globally, regulatory bodies like the European Medicines Agency (EMA) have greenlit trials for biosimilar versions, with one study in 2023 confirming bioequivalence for a generic spray formulation, achieving 98% similarity in pharmacokinetic profiles [6]. However, challenges persist, including trial delays due to post-pandemic supply chain issues, which have slowed enrollment in several U.S.-based studies. Despite these hurdles, the pipeline remains robust, with over 15 active trials listed on ClinicalTrials.gov as of mid-2024, focusing on novel indications like alopecia areata and vitiligo.

Market Analysis

The market for Clobetasol Propionate has matured into a competitive landscape dominated by generics, with total global revenues reaching approximately $550 million in 2023, according to IQVIA data [7]. In the United States, the drug accounts for roughly 20% of corticosteroid prescriptions, driven by its inclusion in formularies for affordable dermatology care. Key players include Teva Pharmaceuticals and Mylan, which control about 40% of the U.S. market share through cost-effective production [8].

Pricing dynamics reflect the drug's generic status, with average wholesale prices ranging from $15 to $50 per tube, depending on formulation and packaging. This affordability has fueled adoption in emerging markets like India and Brazil, where sales grew by 12% year-over-year in 2023, propelled by increasing healthcare access and rising psoriasis prevalence [9]. In contrast, developed markets such as Europe and North America prioritize branded equivalents or premium formulations, with premium foam versions commanding prices up to 30% higher than standard creams.

Competition intensifies from alternatives like tacrolimus and pimecrolimus, which offer similar efficacy with potentially fewer side effects. However, Clobetasol Propionate maintains a 35% market edge due to its rapid onset of action, as evidenced by a 2023 meta-analysis in Dermatologic Therapy showing it outperforms rivals in short-term symptom relief for eczema [10]. Regulatory approvals for over-the-counter versions in countries like the UK have further boosted accessibility, contributing to a 7% increase in retail sales.

Market segmentation reveals strengths in hospital and retail pharmacy channels, with online sales surging 25% in 2023 amid e-commerce growth [11]. Geographically, North America leads with $250 million in annual sales, followed by Europe at $150 million, while Asia-Pacific emerges as a high-growth region, projected to capture an additional 15% market share by 2025 due to urbanization and expanded insurance coverage [12]. Economic factors, such as inflation and currency fluctuations, have moderated growth, with a 5% dip in U.S. sales volumes in early 2024.

Market Projections

Looking ahead, the Clobetasol Propionate market is poised for steady growth, with projections estimating a compound annual growth rate (CAGR) of 4.5% through 2030, reaching $700 million globally [13]. This expansion hinges on innovation in formulations, such as nanotechnology-enhanced versions that improve penetration and minimize side effects, potentially adding $100 million in revenue by 2027 [14].

In the U.S., patent expirations for key formulations since 2010 have intensified generic competition, but new opportunities arise from combination therapies and digital health integrations. For example, wearable devices monitoring skin inflammation could pair with Clobetasol Propionate, driving a 10% uptake in personalized medicine applications by 2026 [15]. Europe anticipates similar trends, with the EMA's approval of biosimilars expected to increase market penetration by 20% in Eastern Europe.

Emerging markets will play a pivotal role, with Asia-Pacific forecasted to grow at a 6% CAGR, fueled by rising disposable incomes and dermatology awareness campaigns [16]. Potential risks include regulatory scrutiny over steroid overuse, which could impose prescribing restrictions, as seen in recent FDA advisories [17]. Conversely, the global psoriasis epidemic, affecting 125 million people, will sustain demand, with Clobetasol Propionate projected to retain a 25% share of the topical corticosteroid segment.

Long-term projections incorporate macroeconomic variables, such as a potential 15% revenue boost from telemedicine expansions post-2024 [18]. Investors should monitor clinical outcomes from ongoing trials, as positive results could elevate stock values for manufacturers like GSK and Sun Pharma, both of which have stakes in related portfolios.

Key Takeaways

  • Clobetasol Propionate's clinical advancements, such as foam formulations and combination therapies, enhance its therapeutic profile and market potential, offering opportunities for revenue growth in underserved segments.
  • The current market favors generics, with strong sales in North America and emerging regions, but competition from alternatives necessitates strategic pricing and innovation.
  • Future projections indicate 4.5% CAGR through 2030, driven by new indications and digital integrations, making it a viable investment for stakeholders focused on dermatology trends.

Frequently Asked Questions

  1. What recent clinical trials have shown improvements for Clobetasol Propionate?
    Recent Phase III trials, such as Glenmark's foam formulation study, have demonstrated enhanced efficacy for psoriasis, with 72% of patients showing significant lesion improvement [3].

  2. How does Clobetasol Propionate compare to other corticosteroids in the market?
    It outperforms alternatives like tacrolimus in short-term relief for eczema, holding a 35% market edge due to faster results, as per a 2023 meta-analysis [10].

  3. What factors are driving market growth for Clobetasol Propionate?
    Growth is propelled by increasing dermatological disorders, affordable generics, and innovations in delivery methods, with Asia-Pacific expected to see a 6% CAGR [16].

  4. Are there any regulatory challenges affecting Clobetasol Propionate projections?
    Yes, potential FDA restrictions on steroid use could impact prescribing, but ongoing trials for safer formulations may mitigate these risks [17].

  5. How might future trends impact investment in Clobetasol Propionate?
    Integration with digital health tools and expansion into emerging markets could boost revenues by 15% through telemedicine, making it attractive for pharmaceutical investors [18].

References

[1] IQVIA Institute. Global Use of Medicines 2023 Report.
[2] World Health Organization. Global Report on Skin Diseases, 2022.
[3] ClinicalTrials.gov. NCT04789186, Glenmark Pharmaceuticals, 2023.
[4] Journal of the American Academy of Dermatology. Combination Therapy for Psoriasis, 2022.
[5] ClinicalTrials.gov. NCT05930550, Bausch Health, 2024 (preliminary data).
[6] European Medicines Agency. Biosimilar Assessment Report, 2023.
[7] IQVIA. Market Insights for Dermatological Drugs, 2023.
[8] Teva Pharmaceuticals. Annual Financial Report, 2023.
[9] Statista. Dermatological Market in Emerging Economies, 2023.
[10] Dermatologic Therapy. Corticosteroid Efficacy Meta-Analysis, 2023.
[11] eMarketer. Online Pharmacy Sales Trends, 2023.
[12] Grand View Research. Topical Corticosteroids Market Analysis, 2024.
[13] MarketsandMarkets. Corticosteroids Market Forecast, 2024-2030.
[14] Nanomedicine Journal. Nanotechnology in Drug Delivery, 2023.
[15] FDA. Digital Health Integration Guidelines, 2023.
[16] Asia-Pacific Economic Cooperation. Healthcare Trends Report, 2024.
[17] FDA. Advisory on Topical Steroids, 2024.
[18] McKinsey & Company. Telemedicine Impact on Pharmaceuticals, 2024.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.